MiRus develops medical implants using a proprietary Molybdenum-Rhenium alloy, MoRe®, which offers superior strength, fatigue resistance, and biocompatibility compared to traditional materials. The company addresses the challenges of spinal and orthopedic degeneration by providing smaller, more durable implants and less invasive surgical solutions that enhance patient outcomes throughout the care continuum.
Funding
$1.6B raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
BSMSFounders
Product
Problem
Traditional spinal and orthopedic implants often suffer from material limitations, leading to potential failures, the need for larger implant sizes, and increased metal ion release into surrounding tissues. These issues can result in revision surgeries and suboptimal patient outcomes.
Solution
MiRus develops and commercializes medical implants using a proprietary Molybdenum-Rhenium alloy, MoRe®, offering enhanced strength, fatigue resistance, and biocompatibility compared to conventional materials like titanium and cobalt chromium. This allows for the creation of smaller, more durable implants designed to reduce the risk of fractures and minimize invasiveness during surgical procedures. MiRus's integrated platform includes pre-operative, intra-operative, and post-operative solutions, featuring innovative implant designs, novel procedural approaches, and advanced remote monitoring systems. The company's solutions span spine, extremity, and structural heart applications, aiming to improve patient outcomes across the continuum of care.
Target Audience
The primary target audience includes spine surgeons, orthopedic surgeons, and cardiovascular surgeons seeking more durable, less invasive implant solutions for their patients.
Features
- Implants constructed from MoRe®, a Molybdenum-Rhenium alloy with superior strength and fatigue resistance
- Smaller implant profiles compared to traditional implants, facilitating less invasive surgical techniques
- Reduced metal ion release into tissue due to the biocompatible nature of MoRe®
- EUROPA® Posterior Cervical System featuring a 2.9 mm MoRe rod for cervicothoracic spine treatment
- Low-profile pedicle screw tulips in the EUROPA® PCF system to minimize hardware prominence
- Remote physiologic monitoring solutions for post-operative patient care